期刊文献+

慢性肾脏疾病患儿维生素D水平研究进展 被引量:2

Vitamin D status in children with chronic kidney disease
原文传递
导出
摘要 儿童慢性肾脏疾病(chronickidneydisease,CKD)是威胁儿童正常生长发育的主要疾病之一,在我国主要病因以肾小球疾病为主,常并发心血管疾病、肾性贫血、肾性骨病等,严重影响儿童生活质量。CKD患儿由于肾脏病变25-羟维生素D[25.(OH)VitD]羟化受到影响、尿毒症导致的皮肤变化使骨化三醇合成减少等因素常引起25-(OH)VitD水平低下。该文就CKD患儿25-(OH)VitD基础水平和影响因素作一综述。 Chronic kidney disease (CKD) is a disease that grately threaten the health of children. In China the main cause of CKD in children is glomerular disease. CKD usually supervene cardiovascular diseases, renal anemia, renal osteodystrophy, and affect the life quality of children greatly. In CKD patients, the hydroxyl- at.ion of 25 (OH) Vitamin D is disordered, and the endogenous synthesis of calcitriol decreased,leading to the re- duce of 25 (OH) Vitamin D. This article will summarize the present researches about the level of 25 (OH) Vita- min D in CKD children in order to provide guidance for the treatment of CKD with Vitamin D.
出处 《国际儿科学杂志》 2013年第5期470-473,共4页 International Journal of Pediatrics
基金 基金项目:甘肃省中药管理局基金项目(GZK-2011-23)
关键词 儿童 慢性肾脏疾病 25-羟维生素D Children Chronic kidney disease 25-hydroxy vitamin D
  • 相关文献

参考文献21

  • 1Ross AC, Taylor CL, Yaktine AL, et al. Dietary Reference Intakes for Calcium and Vitamin D. Washington DC: National Academies Press (US) ,2011 :75-89.
  • 2Razzaghy-Azar M, Shakiba M. Assessment of vitamin D status in healthy children and adolescents living in Tehran and its relation to iPfH,gender, weight and height. Ann Hum Bioi ,2010 ,37 (5) :692- 701.
  • 3Bener A ,AI-Ali M, Hoffmann GF. Vitamin D deficiency in healthy children in a sunny country: associated factors. IntJ Food Sci Nutr, 2009 ,60( Suppl 5) :60-70.
  • 4Stoian CA, Lyon M, Cox RG, et al. Vitamin D concentrations among healthy children in Calgary, Alberta. Paediatr Child Health, 2011 , 16 (2) :82-86.
  • 5李卫国(综述),李宇宁(审校).维生素D缺乏和人类疾病[J].国际儿科学杂志,2011,38(5):474-476. 被引量:21
  • 6林静(综述),刘建(审校).维生素D受体激活剂在慢性肾病及其并发症中的作用[J].国际泌尿系统杂志,2009,29(5):682-685. 被引量:2
  • 7陆铸今.小儿肝、肾功能不全的营养支持[J].中国小儿急救医学,2006,13(2):103-105. 被引量:5
  • 8Querfeld U, Mak RH. Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window. Pediatr Nephrol, 2010 ,25 (12) :2413-2430.
  • 9Foundation NK. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD:2oo8 update. Executive summary. AmJ Kidney Dis ,2009 ,53(3 Suppl2) :Sl1-104.
  • 10Stein DR, Feldman HA, Gordon CM. Vitamin D status in children with chronic kidney disease. Pediatr Nephrol, 2012,27 (8) : 1341- 1350.

二级参考文献52

  • 1向伟,丁宗一,郑维.维生素D及其受体与临床相关疾病的研究[J].中华儿科杂志,2004,42(7):541-544. 被引量:28
  • 2陈雪融,冯玉麟,马玙,张宗德,李传友,文富强,唐晓燕,苏智广.维生素D受体基因多态性与中国藏族结核病的关联研究[J].四川大学学报(医学版),2006,37(6):847-851. 被引量:16
  • 3K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease. Evaluation, classification, and stratification. Am J Kidney Dis,2002, 39 : S1 - 266.
  • 4E. A. Gonzalez. Vitamin D receptor ligand therapy in chronic kidney disease Clinical Nephrology,2008 ,70:271 - 283.
  • 5Xiaoyue Tan. Paricalcitol Inhibits Renal Inflammation by Promoting Vitamin D Receptor - Mediated Sequestration of NF - Kb Signaling. J Am Soc Nephrol , 2008, 19:1741 - 1752.
  • 6Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney int, 2007, 71:31 -38.
  • 7Diego Brancaccio, Jurgen Bommer, Daniel Coyne. Vitamin D Recpetor Activator Selectively in the Treatment of Secondary Hyperparathyroidism. Drugs 2007, 67(14) :1981 - 1998.
  • 8Pietro Ravani, Fabio Malberti, Giavanni Tripepi, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int, 2009, 75 : 88 - 95.
  • 9Brandi L. 1 alpha (OH) D3 One - alpha - hydroxy - cholecalciferol - an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Dan Med Bull. 2008 , 55(4) : 186 -210.
  • 10Andress DL, Vitamin D in chronic kidney disease : a systemic role for selective vitamin D receptor activation. Kidney Int. 2006 , 69( 1 ) :33 -43.

共引文献25

同被引文献66

  • 1王凤英,卢思广,赵彤,李国民.系膜增生型原发性肾病综合征患儿细胞毒性T淋巴细胞相关抗原4基因多态性、蛋白表达及外周血淋巴细胞凋亡的研究[J].中华儿科杂志,2007,45(8):633-634. 被引量:5
  • 2Kong J,Zhang Z,Musch MW,et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier[ J ]. AJP-Gastrointest Liver Physiol, 2008,294 ( 1 ) : G208-G216.
  • 3Lim WC, Hanauer SB, Li YC. Mechanisms of disease: vitamin D andinflammatory bowel disease [ J ]. Nature Clin Pract Gas- troenterol Hepato1,2005,2 : 308 -315.
  • 4Kallay E, Pietschmann P, Toyokuni S, et al. Characterization of a vitamin Dreceptor knockout mouse as a model of colorec- tal hyperproliferation and DNA damage [ J ]. Carcinogenesis, 2001,22 (9) : 1429-1435.
  • 5Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor arecritical for control of the innate immune response to colonic injury[ J]. BMC Immuno,2007 ,18 :5.
  • 6Guo XQ, Wang S J, Zhang LW, et al. DNA methylation and loss of protein expression in esophageal squamous cellcarcino- genesis of high-risk area[ J]. Exp Clin Cancer Res,2007,26: 587 -594.
  • 7Crivori P, Reinach B, Pezzetta D, et al. Computational models for identifying potential P-glycoprotein substrates and inhibi- tors[J]. Mol Pharm,2006,3 ( 1 ) :33.
  • 8Shirasaka Y, Kawasaki M, Sakane T, et al. Induction of human P-gly-coprotein in Caco-2 cells : development of a highly sensi- tive assay system for P-glycoprotein-mediated dmg transport [ J]. Drug Metab Pharmacokinet,2006,21 (5) :414.
  • 9Yamashita S, Furubayashi, Kataoka M, et al. Optimized condi- tions for prediction of intestinal drug permeability using Caco- 2 cells[J]. Eur J Pharm Sci,2000,10(3) ;195.
  • 10Fossati L, Dechaume R, Hardillier E, et al. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs [J]. Int J Pharm,2008,360(1-2) :148.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部